| Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. F Caligaris-Cappio, M Gobbi, M Bofill, G Janossy The Journal of experimental medicine 155 (2), 623-628, 1982 | 607 | 1982 |
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic … P Le Coutre, OG Ottmann, F Giles, DW Kim, J Cortes, N Gattermann, ... Blood, The Journal of the American Society of Hematology 111 (4), 1834-1839, 2008 | 383 | 2008 |
| Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts AM Raiola, A Dominietto, C di Grazia, T Lamparelli, F Gualandi, A Ibatici, ... Biology of Blood and Marrow Transplantation 20 (10), 1573-1579, 2014 | 327 | 2014 |
| Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study F Frassoni, F Gualandi, M Podestà, AM Raiola, A Ibatici, G Piaggio, ... The Lancet Oncology 9 (9), 831-839, 2008 | 314 | 2008 |
| Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia RJ Kreitman, C Dearden, PL Zinzani, J Delgado, L Karlin, T Robak, ... Leukemia 32 (8), 1768-1777, 2018 | 256 | 2018 |
| Vδ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid A Poggi, C Venturino, S Catellani, M Clavio, M Miglino, M Gobbi, A Steinle, ... Cancer research 64 (24), 9172-9179, 2004 | 215 | 2004 |
| International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia GJ Roboz, T Rosenblat, M Arellano, M Gobbi, JK Altman, P Montesinos, ... Journal of clinical oncology 32 (18), 1919-1926, 2014 | 213 | 2014 |
| Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors A Poggi, C Prevosto, AM Massaro, S Negrini, S Urbani, I Pierri, ... The Journal of Immunology 175 (10), 6352-6360, 2005 | 203 | 2005 |
| Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma PL Zinzani, E Pavone, S Storti, L Moretti, PP Fattori, L Guardigni, B Falini, ... Blood, The Journal of the American Society of Hematology 89 (11), 3974-3979, 1997 | 198 | 1997 |
| Elderly aggressive-histology non-Hodgkin’s lymphoma: first-line VNCOP-B regimen experience on 350 patients PL Zinzani, S Storti, A Zaccaria, L Moretti, M Magagnoli, E Pavone, ... Blood, The Journal of the American Society of Hematology 94 (1), 33-38, 1999 | 194 | 1999 |
| Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma PL Zinzani, A Pulsoni, A Perrotti, S Soverini, F Zaja, A De Renzo, S Storti, ... Journal of clinical oncology 22 (13), 2654-2661, 2004 | 192 | 2004 |
| BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients G Visani, L Malerba, PM Stefani, S Capria, P Galieni, F Gaudio, ... Blood, The Journal of the American Society of Hematology 118 (12), 3419-3425, 2011 | 170 | 2011 |
| Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells D de Totero, R Meazza, S Zupo, G Cutrona, S Matis, M Colombo, ... Blood 107 (9), 3708-3715, 2006 | 161 | 2006 |
| Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition M Cea, A Cagnetta, M Fulciniti, YT Tai, T Hideshima, D Chauhan, ... Blood, The Journal of the American Society of Hematology 120 (17), 3519-3529, 2012 | 157 | 2012 |
| CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells MP Pistillo, PL Tazzari, GL Palmisano, I Pierri, A Bolognesi, F Ferlito, ... Blood, The Journal of the American Society of Hematology 101 (1), 202-209, 2003 | 156 | 2003 |
| Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas J Gerdes, H Stein, S Pileri, MT Rivano, M Gobbi, E Ralfkiaer, KM Nielsen, ... The Lancet 330 (8556), 448-449, 1987 | 154 | 1987 |
| FLAG (fludarabine+ high-dose cytarabine+ G-CSF): an effective and tolerable protocol for the treatment of'poor risk'acute myeloid leukemias. G Visani, P Tosi, PL Zinzani, S Manfroi, E Ottaviani, N Testoni, M Clavio, ... Leukemia 8 (11), 1842-1846, 1994 | 152 | 1994 |
| Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies M Gobbi, F Caligaris‐Cappio, G Janossy British Journal of Haematology 54 (3), 393-403, 1983 | 152 | 1983 |
| Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma P Tosi, E Zamagni, C Cellini, S Ronconi, F Patriarca, F Ballerini, P Musto, ... Journal of the Peripheral Nervous System 7 (3), 209-209, 2002 | 144 | 2002 |
| High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas MR Zocchi, S Catellani, P Canevali, S Tavella, A Garuti, B Villaggio, ... Blood, The Journal of the American Society of Hematology 119 (6), 1479-1489, 2012 | 143 | 2012 |
pier paolo piccalugaProfessore Associato, Università degli Studi di Bologna在 unibo.it 的电子邮件经过验证
pier paolo piccalugaProfessore Associato, Università degli Studi di Bologna在 unibo.it 的电子邮件经过验证